FDA-approved GLP-1 receptor agonists (including semaglutide, dulaglutide, liraglutide, and others) are indicated for adults with type 2 diabetes as adjuncts to diet and exercise to improve glycemic control
Firstly, GLP-1 receptor agonists can re-establish appetite suppression that may have diminished over time as the body adapts to surgical changes
Taken together, these findings suggest that balanced protein distribution across meals and strategic timing of intake around resistance exercise may enhance muscle mass preservation, however, the optimal feeding pattern is likely context-dependent and influenced by age, nutritional status and comorbidities
This provides a solid rationale for exploring their use in T1D, especially since overweight and obesity are common concerns in both types of diabetes
GLP-1 drugs are often discussed in terms of weight loss, blood sugar, and appetite control